Clinical Trial Detail

NCT ID NCT01822509
Title Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

multiple myeloma

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

myelodysplastic/myeloproliferative neoplasm

chronic lymphocytic leukemia

Therapies

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.